FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine and pharmaceuticals, namely, to an application of mefloquine as a medicinal agent against an infection caused by the SARS-CoV-2 virus, in the amount of 500 mg of mefloquine per day, for four days of treatment. Preferably, the agent is administered twice a day orally or gastroenterically.
EFFECT: invention provides an acceleration of elimination of the viral RNA, a reduction in the duration of treatment, a lighter course of the disease, and a reduction in the severity of symptoms.
3 cl, 3 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| METHOD FOR PROTECTION AGAINST CORONAVIRUS INFECTION | 2020 |
|
RU2747467C1 |
| METHOD FOR COVID-19 PNEUMONIA TREATMENT | 2020 |
|
RU2745535C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH NEW CORONAVIRUS INFECTION (COVID-19) | 2020 |
|
RU2745774C1 |
| MODIFIED ANTISENSE OLIGONUCLEOTIDE AGAINST SARS-CoV-2 | 2020 |
|
RU2750584C1 |
| METHOD FOR PREVENTIVE TREATMENT OF CORONAVIRUS INFECTION | 2020 |
|
RU2777462C2 |
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
| METHOD FOR THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2775966C1 |
| 2-(IMIDAZOL-4-YL)-ETHANAMIDE OF PENTANEDIOIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING COVID-19 AND SYMPTOMS THEREOF | 2021 |
|
RU2824607C2 |
| METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
